COVID-19 Vaccines Industry Study

Resurgences in COVID-19 outbreaks have made it clear that ending the pandemic will require more than diagnostics, contact tracing, and social distancing. Gilead's Veklury (remdesivir) and other treatments are likely to improve mortality rates, but an effective vaccine will be necessary to end the pandemic. While strong antibody and T-cell responses in several Phase 1 studies of COVID-19 vaccines don't guarantee protection against infection or severe disease, we're increasingly bullish that most of the vaccines entering late-stage development in the U.S. will meet Food and Drug Administration guidelines for approval (50% risk reduction).

In this industry report, you will learn:
  • The potential value of the COVID-19 vaccine market in 2021
  • Which available treatments are most likely to profit
  • Innovation in prevention and treatment programs
  • The impact of potential competition from oral treatments on sales in 2021
Sign up to receive your copy:
Sign up to receive your copy: